Dr. Rikki Waterhouse, Founder and Principal Consultant for Waterhouse Imaging and Biomarkers Consultants (WIBC), has over 25 years’ experience in radiopharmaceutical development and biomedical imaging in academic and industrial settings. Rikki completed her undergraduate studies and her Ph.D in Chemistry (organic and radiochemistry) at the University of TN, Knoxville. Her professional interests includes the use of imaging to better understand pharmacology, physiology, drug deposition, with the aim of developing better pharmaceutical drugs. While her particular area of expertise is nuclear tomographic imaging (PET and SPECT), including radiotracer development in the preclinical and clinical space, Rikki also has a working knowledge of other imaging modalities and non-imaging biomarker assays that facilitate overall derivation of comprehensive, translational biomarker strategies.
During her academic career (Duke University and Columbia University, Asst/Assoc Professor), Rikki directed laboratories focused on the design, synthesis and evaluation of novel radiotracers for preclinical and clinical imaging studies. She mentored postdoctoral and medical fellows and junior faculty, and drove the clinical imaging work to evaluate these compounds in clinic, serving as sponsor on IND and PI on clinical imaging protocols. This experience was further expanded in her career in Pharma (Merck, Abbott, Pfizer), where she worked with clinical teams to write protocols and INDs for clinical imaging studies and took responsibility for their technical execution. Rikki is an active member of several biomedical imaging societies, and is a full member of the American College of Neuropsychopharmacology (ACNP). She is primary author or co-author on 37 original publications as well as over 120 scientific abstracts, and several editorials and book chapters